ASIA-PACIFIC SODIUM-DEPENDENT GLUCOSE COTRANSPORTER 2 (SGLT-2) MARKET - GROWTH, TRENDS, COVID-19 IMPACT, and Forecasts (2023 - 2028)

The Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market is segmented into Drugs (Invokana, Jardiance, Farxiga/Forxiga, and Suglat) and Geography. The report offers the value (in USD million) for the above segments.

Home right-chevron-icon Industry Reports right-chevron-icon Healthcare right-chevron-icon Diabetes Drugs & Devices right-chevron-icon Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market

APAC SGLT2 Market Size

APAC Sodium-Dependent Glucose Cotransporter 2 (SGLT2) market Overview
Study Period: 2018 - 2028
CAGR: > 8 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order
setting-icon

Need a report that reflects how COVID-19 has impacted this market and it's growth?

APAC SGLT2 Market Analysis

The Asia-Pacific Sodium-dependent Glucose Cotransporter 2 market is set to witness a CAGR of more than 8% during the forecast period 2022-2027.

The COVID-19 pandemic positively impacted the Asia-Pacific Sodium-Dependent Glucose Cotransporter 2 market. People with diabetes have a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people. The manufacturers of diabetes drugs have taken care during COVID-19 to deliver the medications to diabetes patients with the help of local governments. NovoNordisk stated on their website that “Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.”

SGLT-2 inhibitors also called gliflozins are a class of medicine used to lower high blood glucose levels in people with type 2 diabetes. SGLT-2 drugs have a significant role in managing cardiovascular risk factors including blood pressure, glycemia, weight, cardiac function, and anti‐inflammatory activity. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic.

The Asia-pacific region had witnessed an alarming increase in the prevalence of diabetes, in recent years. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as medications or ingestion of additional carbohydrates by monitoring their blood glucose levels. Diabetes mellitus has been of wide concern with its high prevalence, resulting in increased financial burdens for clinical systems, individuals, and governments. The market players are adopting various strategies such as collaborations, partnerships, mergers, acquisitions, and expansions to increase market share. Technological advancements have increased over the period leading to several modifications either in the SGLT-2 inhibitors or the formulations being developed.

Therefore, due to increased prevalence and the aforementioned factors, the studied market is anticipated to witness growth over the analysis period.

APAC SGLT2 Industry Segmentation

The Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market is segmented into Drugs (Invokana, Jardiance, Farxiga/Forxiga, and Suglat) and Geography. The report offers the value (in USD million) for the above segments.

Drug
Sodium-dependent Glucose Cotransport 2 (SGLT-2) Inhibitor (Value and Volume, 2016-2027)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Geography
Japan (Value and Volume 2016-2027)
Drug (Invokana, Jardiance, Farxiga, Suglat)
South Korea (Value and Volume 2016-2027)
Drug (Invokana, Jardiance, Farxiga, Suglat)
China (Value and Volume 2016-2027)
Drug (Invokana, Jardiance, Farxiga, Suglat)
India (Value and Volume 2016-2027)
Drug (Invokana, Jardiance, Farxiga, Suglat)
Australia (Value and Volume 2016-2027)
Drug (Invokana, Jardiance, Farxiga, Suglat)
Vietnam (Value and Volume 2016-2027)
Drug (Invokana, Jardiance, Farxiga, Suglat)
Malaysia (Value and Volume 2016-2027)
Drug (Invokana, Jardiance, Farxiga, Suglat)
Indonesia (Value and Volume 2016-2027)
Drug (Invokana, Jardiance, Farxiga, Suglat)
Philippines (Value and Volume 2016-2027)
Drug (Invokana, Jardiance, Farxiga, Suglat)
Thailand (Value and Volume 2016-2027)
Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Asia-Pacific (Value and Volume 2016-2027)
Drug (Invokana, Jardiance, Farxiga, Suglat)

Report scope can be customized per your requirements. Click here.

APAC SGLT2 Market Trends

This section covers the major market trends shaping the APAC SGLT2 Market according to our research experts:

Jardiance Segment held the highest market share in the Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market in 2021

Jardiance holds the highest market share in the Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market with a revenue of more than USD 1 billion as of 2021 and is expected to register a CAGR of more than 10% during the forecast period 2022-2027.

Jardiance is a prescription medicine used to lower blood sugar along with diet and exercise in adults with type 2 diabetes. It reduces the risk of cardiovascular death in adults with type 2 diabetes who also have known cardiovascular disease. Jardiance also reduces the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, when the heart cannot pump enough blood to the rest of the body. It is not for people with type 1 diabetes.

SGLT-2 inhibitor drugs have been available internationally and are recommended for use when escalation of treatment for type 2 diabetes is required along with lifestyle management. Oral agents are typically the first medications used in the treatment of type 2 diabetes due to their wide range of efficacy, safety, and mechanisms of action. SGLT-2 inhibitor drugs help diabetes patients to keep their condition under control and lower the risk of diabetes complications. People with diabetes may need to take antidiabetic drugs for their whole lives to control their blood glucose levels and avoid hypoglycemia and hyperglycemia. These agents present the advantages of easier management and lower cost, so they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.

According to International Diabetes Federation (IDF), 90 million adults (20-79) are living with diabetes in the IDF South-East Asia (SEA) Region in 2021. This figure is estimated to increase to 152 million by 2045 and 206 million adults (20-79) are living with diabetes in the IDF Western Pacific Region in 2021 which is estimated to increase to 260 million by 2045. The Asia-Pacific region had witnessed an alarming increase in the prevalence of diabetes, in recent years. In developing countries, such as China and India, the rate of diabetes is at an all-time high. Also, the use of oral anti-diabetes drugs is rising because new generation drugs reduce the rate of CV risk in diabetes patients. Leading manufacturers are focusing on technological innovations and the development of advanced products to gain a substantial share of the market.

Type-2 diabetes population

Japan is expected to dominate Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market in terms of revenue

Japan is expected to grow with a CAGR of more than 8.5% in the Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market.

Japan has around 11 million people with diabetes according to IDF 2021 data. While Type 1 diabetes is caused by an immune system malfunction, Type 2 diabetes is linked to leading a sedentary lifestyle, which results in the development of inherent resistance to insulin. Japan has one of the largest elderly populations in the world which is more susceptible to the onset of type 2 diabetes. As Japan’s population continues to age, the prevalence of diabetes increases as well. The rise in the number of people with type 2 is driven by a complex interplay of socio-economic, demographic, environmental, and genetic factors. Key contributors include urbanization, an aging population, decreasing levels of physical activity, and increased levels of overweight and obesity.

Much can be done to reduce the impact of diabetes. Evidence suggests that type 2 diabetes can often be prevented, while early diagnosis and access to appropriate care for all types of diabetes can avoid or delay complications in people living with the condition. When diabetes is undetected or inadequately treated, people with diabetes are at risk of serious and life-threatening complications, such as heart attack, stroke, kidney failure, blindness, and lower-limb amputation. These result in reduced quality of life and higher healthcare costs.

Diabetes has been identified as a healthcare priority by the Ministry of Health, Labour and Welfare (MHLW). The costs of diabetes are increased in patients with co-morbidities such as hypertension and hyperlipidemia and in patients who develop complications. Costs increase with an increasing number of complications. Well-organized medical insurance systems cover all medical fees for diabetes mellitus, and diabetics can visit doctors freely in Japan.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the Asia-Pacific Region.

Revenue share

APAC SGLT2 Industry Overview

The Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market is highly consolidated, with major manufacturers namely Eli Lilly, Sanofi, and Novo Nordisk having a global and regional market presence. The joint ventures that occurred between players in the recent past have helped the companies strengthen their market presence. For example, Eli Lilly and Boehringer Ingelheim make Jardiance together, which is a very popular SGLT-2 class drug.

APAC SGLT2 Market Leaders

  1. Astrazeneca

  2. Eli Lilly

  3. Boehringer Ingelheim

  4. Janssen Pharmaceuticals

*Disclaimer: Major Players sorted in no particular order

APAC SGLT2 COMP.png

APAC SGLT2 Market News

  • In April 2022, Nippon Boehringer Ingelheim’s SGLT-2 inhibitor Jardiance (empagliflozin) obtained a label update from PMDA in Japan allowing its use in patients with chronic heart failure with preserved ejection fraction (HFpEF) in addition to those with heart failure with reduced ejection fraction (HFrEF).
  • In February 2021, AstraZeneca’s Forxiga (dapagliflozin) was approved in China to reduce the risk of cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF).

APAC SGLT2 Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Drug

      1. 5.1.1 Sodium-dependent Glucose Cotransport 2 (SGLT-2) Inhibitor (Value and Volume, 2016-2027)

        1. 5.1.1.1 Invokana (Canagliflozin)

        2. 5.1.1.2 Jardiance (Empagliflozin)

        3. 5.1.1.3 Farxiga/Forxiga (Dapagliflozin)

        4. 5.1.1.4 Suglat (Ipragliflozin)

    2. 5.2 Geography

      1. 5.2.1 Japan (Value and Volume 2016-2027)

        1. 5.2.1.1 Drug (Invokana, Jardiance, Farxiga, Suglat)

      2. 5.2.2 South Korea (Value and Volume 2016-2027)

        1. 5.2.2.1 Drug (Invokana, Jardiance, Farxiga, Suglat)

      3. 5.2.3 China (Value and Volume 2016-2027)

        1. 5.2.3.1 Drug (Invokana, Jardiance, Farxiga, Suglat)

      4. 5.2.4 India (Value and Volume 2016-2027)

        1. 5.2.4.1 Drug (Invokana, Jardiance, Farxiga, Suglat)

      5. 5.2.5 Australia (Value and Volume 2016-2027)

        1. 5.2.5.1 Drug (Invokana, Jardiance, Farxiga, Suglat)

      6. 5.2.6 Vietnam (Value and Volume 2016-2027)

        1. 5.2.6.1 Drug (Invokana, Jardiance, Farxiga, Suglat)

      7. 5.2.7 Malaysia (Value and Volume 2016-2027)

        1. 5.2.7.1 Drug (Invokana, Jardiance, Farxiga, Suglat)

      8. 5.2.8 Indonesia (Value and Volume 2016-2027)

        1. 5.2.8.1 Drug (Invokana, Jardiance, Farxiga, Suglat)

      9. 5.2.9 Philippines (Value and Volume 2016-2027)

        1. 5.2.9.1 Drug (Invokana, Jardiance, Farxiga, Suglat)

      10. 5.2.10 Thailand (Value and Volume 2016-2027)

        1. 5.2.10.1 Drug (Invokana, Jardiance, Farxiga, Suglat)

      11. 5.2.11 Rest of Asia-Pacific (Value and Volume 2016-2027)

        1. 5.2.11.1 Drug (Invokana, Jardiance, Farxiga, Suglat)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2016-2027)

    2. 6.2 Type-2 Diabetes Population (2016-2027)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 COMPANY PROFILES

      1. 7.1.1 Eli Lilly

      2. 7.1.2 Janssen Pharmaceuticals

      3. 7.1.3 Boehringer Ingelheim

      4. 7.1.4 AstraZeneca

      5. 7.1.5 Bristol Myers Squibb

    2. 7.2 MARKET SHARE ANALYSIS

      1. 7.2.1 Eli Lilly

      2. 7.2.2 AstraZeneca

      3. 7.2.3 Others

  8. 8. MARKET OPPORTUNITES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

APAC SGLT2 Market Research FAQs

The Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market is studied from 2018 - 2028.

The Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market is growing at a CAGR of >8% over the next 5 years.

The Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market is valued at 1541 Million USD in 2018.

The Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market is valued at 2348 Million USD in 2028.

Astrazeneca, Eli Lilly, Boehringer Ingelheim, Janssen Pharmaceuticals are the major companies operating in Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Market.

Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) Industry Report

Statistics for the 2023 Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Asia-Pacific Sodium-dependent Glucose Cotransporter 2 (SGLT-2) analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!